Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
This article illustrates a consensus opinion of an expert panel on the need and usefulness of a framework for price and reimbursement (P&R) process and managed entry agreements (MEAs) for orphan medicines in Italy. This opinion was gathered in three rounds: an introductory document was sent to...
Main Authors: | Claudio Jommi, Antonio Addis, Nello Martini, Elena Nicod, Marcello Pani, Annalisa Scopinaro, Sabine Vogler |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2021-08-01
|
Series: | Global & Regional Health Technology Assessment |
Subjects: | |
Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2278 |
Similar Items
-
The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
by: Entela Xoxi, et al.
Published: (2021-08-01) -
A systematic review of moral reasons on orphan drug reimbursement
by: Bettina M. Zimmermann, et al.
Published: (2021-06-01) -
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
by: Krzysztof Piotr Malinowski, et al.
Published: (2019-05-01) -
Analysing criteria for price and reimbursement of orphan drugs in Spain
by: Xavier Badia, et al.
Published: (2019-07-01) -
How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
by: Peiravian, F., et al.
Published: (2022)